TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10943739

Group type: EXPERIMENTAL
Intervention: GH‐1 gene deletion screening using PCR method
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Direct sequencing analysis
Number of subjects: 48
Study: 10102659

Group type: EXPERIMENTAL
Intervention: Human milk (n=16)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard term formula (F) (n=15)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Formula with egg yolk lecithin providing DHA (0.15%) and AA (0.30%) (LCP-F) (n=18)
Number of subjects: 49
Study: 7919671

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg/L) and heparin (500 U/L) added to peripheral intravenous fluid (feed A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral intravenous fluid without heparin and hydrocortisone (feed B)
Number of subjects: 0
Study: 2904523

Group type: EXPERIMENTAL
Intervention: Adrenaline (15 ng/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noradrenaline (30 ng/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% dextrose solution (5.4 ml/h)
Number of subjects: 10
Study: 31323771

Group type: EXPERIMENTAL
Intervention: Lunch at a restaurant/take-out (n = 84, 4%)
Number of subjects: 2075

Group type: COMPARATOR
Intervention: Post-policy food outlet access within 1000 m of schools
Number of subjects: 2075

Group type: COMPARATOR
Intervention: Overall food outlet numbers over time
Number of subjects: 2075
Study: 29305401

Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention (low-calorie diet)
Number of subjects: 510
Study: 26956188

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol·kg–1·min–1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 24271347

Group type: EXPERIMENTAL
Intervention: Cell-phone support with study funded phone plans
Number of subjects: 37
Study: 21599819

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg bid with tenofovir/emtricitabine
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg bid with optimized background therapy
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Efavirenz 600 mg at bedtime with tenofovir/emtricitabine
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo with optimized background therapy
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 1262
Study: 19067473

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17991641

Group type: COMPARATOR
Intervention: Low-fat (LF) diet providing 30.8% of energy from fat and 5.2% from polyunsaturated fat (PUFA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet providing 37.9% of energy from fat and 5.8% from PUFA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-PUFA (HPUFA) diet providing 36.3% of energy from fat and 9.7% from PUFA
Number of subjects: 24
Study: 16786773

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative brachytherapy
Number of subjects: 0
Study: 12230933

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 mg/day)
Number of subjects: 123
Study: 10684216

Group type: EXPERIMENTAL
Intervention: Emoxipin (2-week monotherapy)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 7539202

Group type: EXPERIMENTAL
Intervention: H&E-stained smears of papillary carcinoma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MGG-stained smears of papillary carcinoma
Number of subjects: 34
Study: 2156341

Group type: EXPERIMENTAL
Intervention: Epidural redose of 2% chloroprocaine buffered with sodium bicarbonate in the upright position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural redose of 2% chloroprocaine buffered with sodium bicarbonate in the supine position
Number of subjects: 30
Study: 218154

Group type: EXPERIMENTAL
Intervention: 3 percent vidarabine applied topically six times daily for 7 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (identically packaged)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3 percent vidarabine applied topically
Number of subjects: 76
Study: 7037982

Group type: EXPERIMENTAL
Intervention: Three doses of Salmonella typhi strain Ty 21a oral vaccine (1‐8 X 10(9) live Ty 21a bacteria per dose)
Number of subjects: 32388

Group type: COMPARATOR
Intervention: Placebo (three doses)
Number of subjects: 32388
Study: 31816452

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 338
Study: 30311771

Group type: EXPERIMENTAL
Intervention: Social exclusion in an online ball-tossing game
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Stronger anthropomorphism
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Greater instrumental and sentimental values
Number of subjects: 331
Study: 27061921

Group type: EXPERIMENTAL
Intervention: Carboplatin and Vincristine (CV) for NF1 patients
Number of subjects: 127

Group type: COMPARATOR
Intervention: Carboplatin and Vincristine (CV) for non-NF1 patients
Number of subjects: 127
Study: 22967171

Group type: COMPARATOR
Intervention: Implants placed in maxillary native bone (group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Implants placed in sinus-grafted sites (group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Implants placed in group B1 (simultaneous insertion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Implants placed in group B2 (6 months after sinus lift)
Number of subjects: 25
Study: 21774840

Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars (130 mg quercetin equivalents)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Quercetin powder-filled hard capsules (130 mg quercetin equivalents)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars
Number of subjects: 6

Group type: COMPARATOR
Intervention: Quercetin powder-filled hard capsules
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quercetin-enriched cereal bars and quercetin powder-filled hard capsules
Number of subjects: 6
Study: 19620164

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 6695

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 6695
Study: 17766567

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) group, 11-week duration
Number of subjects: 152

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 152
Study: 15188898

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laser epithelial keratomileusis (LASEK)
Number of subjects: 32

Group type: COMPARATOR
Intervention: LASIK and LASEK
Number of subjects: 32
Study: 11791088

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 40
Study: 10896360

Group type: EXPERIMENTAL
Intervention: Grid laser treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 8677036

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg vecuronium
Number of subjects: 40
Study: 2187665

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, single oral dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22
Study: 7362132

Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 11
Study: 31801154

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery after Surgery (ERAS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conservative regimen
Number of subjects: 35
Study: 30828946

Group type: EXPERIMENTAL
Intervention: ECAP-controlled closed-loop SCS
Number of subjects: 134

Group type: COMPARATOR
Intervention: Open-loop conventional SCS
Number of subjects: 134
Study: 28975304

Group type: EXPERIMENTAL
Intervention: Oral cephalexin 500 mg and metronidazole 500 mg every 8 hours for 48 hours
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo every 8 hours for 48 hours
Number of subjects: 403
Study: 25799446

Group type: EXPERIMENTAL
Intervention: AH Plus® sealer with immediate post space preparation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: AH Plus® sealer with delayed post space preparation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MTA Fillapex® sealer with immediate post space preparation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MTA Fillapex® sealer with delayed post space preparation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Positive control groups (no treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Negative control groups (no treatment)
Number of subjects: 76
Study: 22906553

Group type: EXPERIMENTAL
Intervention: Ketamine at a psychotomimetic dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 10
Study: 21116825

Group type: EXPERIMENTAL
Intervention: Continuous progressive exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Strenuous exercise until exhaustion
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acute bout of exercise at 70% of maximal work capacity for 30 min
Number of subjects: 34

Group type: COMPARATOR
Intervention: Submaximal workload
Number of subjects: 34
Study: 19240251

Group type: EXPERIMENTAL
Intervention: GHRH and GHRP-2 infusion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Testosterone (T) restoration after leuprolide
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fasting pulsatile GH secretion
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GHRH-GHRP synergy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Estradiol (E(2))
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IGF-I
Number of subjects: 47
Study: 17976101

Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients presenting with stable ventricular tachycardia (VT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients with ischemic etiology
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients with tiered therapy programmed ICDs
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ICD therapy delivered to patients using beta-blockers
Number of subjects: 161

Group type: COMPARATOR
Intervention: Time to first appropriate therapy between first and second ICDs
Number of subjects: 161
Study: 14679381

Group type: EXPERIMENTAL
Intervention: E+ (sucrose, 100 g/l, 1672 kJ)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: E+ (sucrose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: E- (intense sweeteners)
Number of subjects: 24
Study: 11887021

Group type: EXPERIMENTAL
Intervention: Daily mouthrinse with triclosan-zinc for 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray for 2 weeks
Number of subjects: 37
Study: 10438868

Group type: EXPERIMENTAL
Intervention: Intranasal spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two nasal spray vaccinations with 7.5 micrograms of HA with 1 microgram of HLT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single spray vaccination with 15 micrograms of HA and 2 micrograms of HLT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parenteral virosomal vaccine with 15 micrograms of HA without additional adjuvant
Number of subjects: 60
Study: 8658281

Group type: EXPERIMENTAL
Intervention: Combination of pefloxacin (Abaktal) and clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study: 2272604

Group type: EXPERIMENTAL
Intervention: Tolazamide (daily oral weight-adjusted)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7450653

Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Retard tablet (enteric-coated)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Suppository (Euphyllin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous preparation
Number of subjects: 8
Study: 31658037

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation treatment group (OMTG - n=23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active control group (ACG - n=19)
Number of subjects: 42
Study: 29644473

Group type: EXPERIMENTAL
Intervention: ACTIVATE™ computer training for 8 weeks
Number of subjects: 70
Study: 26356254

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 10
Study: 25053388

Group type: EXPERIMENTAL
Intervention: 40 mg veliparib (new formulation) under fasting conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Four 10 mg current formulation capsules under fasting conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Four 10 mg new formulation under fasting conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: High-fat meal effect on veliparib
Number of subjects: 36
Study: 22664754

Group type: EXPERIMENTAL
Intervention: Machine-assisted cycling
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional ET
Number of subjects: 27
Study: 20421537

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (paclitaxel at 175 mg/m² IV over 3 hours plus carboplatin AUC = 6 IV over 30 minutes every 3 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Number of subjects: 46
Study: 18826988

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 or 600 mg for 1 day; 300 + 75 or 150 mg daily for 7 days)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Platelet function tests (light transmission aggregometry, whole-blood aggregometry, PFA-100, VerifyNow P2Y12)
Number of subjects: 116
Study: 15766390

Group type: EXPERIMENTAL
Intervention: Adaptive filtering method for 16.7 Hz interference suppression
Number of subjects: 0
Study: 12472704

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.3 mg.kg‐1
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg(‐1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Rectal midazolam 0.5 mg.kg(‐1)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 0.3 mg.kg(‐1)
Number of subjects: 119
Study: 10860225

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0
Study: 8690204

Group type: EXPERIMENTAL
Intervention: H. pylori-infected subjects before eradication
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: H. pylori-infected subjects after eradication
Number of subjects: 16

Group type: COMPARATOR
Intervention: H. pylori-negative controls
Number of subjects: 16
Study: 1805295

Group type: EXPERIMENTAL
Intervention: Ethanol 1 g/kg body weight
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg body weight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6137975

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham electrical stimulation (Control)
Number of subjects: 44
Study: 29903051

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29597006

Group type: EXPERIMENTAL
Intervention: Dyadic participation in a lifestyle intervention
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Individual participation in a lifestyle intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 460
Study: 27084954

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 483

Group type: COMPARATOR
Intervention: Methotrexate 40 mg/m2/week
Number of subjects: 483
Study: 25243574

Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64) with TSH ≥ 5 mIU/L
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: T4 treatment (N = 64) with TSH < 5 mIU/L
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo treatment (N = 59)
Number of subjects: 123
Study: 22252342

Group type: EXPERIMENTAL
Intervention: Sequential Feeding (SF)
Number of subjects: 1320
Study: 20728265

Group type: EXPERIMENTAL
Intervention: RRP (Retropubic Radical Prostatectomy)
Number of subjects: 1787

Group type: COMPARATOR
Intervention: Watchful Waiting (WW)
Number of subjects: 1787

Group type: COMPARATOR
Intervention: Control (nonoperated patients with PCa)
Number of subjects: 1787

Group type: EXPERIMENTAL
Intervention: RALP (Robot-Assisted Radical Prostatectomy)
Number of subjects: 1787

Group type: COMPARATOR
Intervention: Control (matched controls without PCa)
Number of subjects: 1787
Study: 17286338

Group type: EXPERIMENTAL
Intervention: Neighborhood-based interventions (including mobilization, community awareness, responsible beverage service, underage-access law enforcement, intoxicated-patron law enforcement)
Number of subjects: 0
Study: 16047525

Group type: EXPERIMENTAL
Intervention: S Model (mid-level professionals, usually nurses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: P Model (medical providers)
Number of subjects: 10
Study: 12364554

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 10427668

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 7485222

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen three times daily for 1 month
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam daily for 1 month
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 mg sulindac twice daily for 1 month
Number of subjects: 29
Study: 1485584

Group type: EXPERIMENTAL
Intervention: HLBI 3 MU intramuscularly 6 days a week (arm A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: HLBI 1 MU intramuscularly 6 days a week (arm B)
Number of subjects: 31
Study: 4023472

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment A or B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment C or D
Number of subjects: 0
Study: 28745470

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (3 g of taurine with 400 mL low fat chocolate milk)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) with 400 mL low fat chocolate milk
Number of subjects: 9
Study: 27703983

Group type: EXPERIMENTAL
Intervention: McGRATH MAC
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: C-MAC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 39
Study: 26425113

Group type: EXPERIMENTAL
Intervention: Interactive educational sessions based on WHO Primary Ear and Hearing Resource, Basic Level.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual monthly group meetings (Control).
Number of subjects: 30
Study: 23228858

Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 250
Study: 21617573

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (2 doses, 6 to 9 months apart)
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine coadministered with MMR and varicella vaccines (2 doses of hepatitis A vaccine, 6 to 9 months apart)
Number of subjects: 1241

Group type: COMPARATOR
Intervention: MMR and varicella vaccines followed by 2 doses of hepatitis A vaccine (6 weeks later, 6 to 9 months apart)
Number of subjects: 1241
Study: 18784962

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 99
Study: 16865082

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.5% (group B)
Number of subjects: 60
Study: 12699469

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 micro g daily)
Number of subjects: 1312
Study: 10828725

Group type: EXPERIMENTAL
Intervention: Protein kinase C activation with 4beta‐12‐tetradecanoylphorbol 13‐acetate (beta‐TPA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study: 9603637

Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg once-daily (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg twice-daily (Group B)
Number of subjects: 86
Study: 7930762

Group type: EXPERIMENTAL
Intervention: High HAMA levels in serum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low HAMA levels in serum
Number of subjects: 0
Study: 3350994

Group type: EXPERIMENTAL
Intervention: Prednisone (PN) 10-mg oral tablet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prednisolone (PL) 10-mg oral tablet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous Prednisone (IV PN) 10-mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous Prednisolone (IV PL) 10-mg
Number of subjects: 8
Study: 28548898

Group type: EXPERIMENTAL
Intervention: Rapid albuterol pathway with a breath-enhanced nebulizer (up to 4 treatments)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment arm (up to 2 continuous albuterol nebulizations)
Number of subjects: 50
Study: 26059708

Group type: EXPERIMENTAL
Intervention: RC Fill (zinc oxide‐eugenol with iodoform)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Vitapex (calcium hydroxide with iodoform)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pulpdent root canal sealer (ZOE)
Number of subjects: 129
Study: 25211372

Group type: EXPERIMENTAL
Intervention: Yoga intervention (12 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 0